Clinical Trial

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent designed in the laboratory to block only tumor blood vessels, not blood vessels in the normal liver.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-10-19; most recent amendment 2025-03-04.
Status change: Not Yet Recruiting → Recruiting 2021-03-01
Trial Details
NCT Number NCT04601428
Lead Sponsor Koo Foundation Sun Yat-Sen Cancer Center
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 43 participants
Start Date 2021-01-26
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-06